ReviewTranslational andrology and urology2025
Current management strategies for bladder neck stenosis and vesicourethral anastomotic stenosis.
Review in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paclitaxel Drug-Coated Balloon (OptilumeMedicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder neck stenosis (BNS) and vesicourethral anastomotic stenosis (VUAS) are forms of posterior urethral narrowing, typically resulting from benign prostate surgery and radical prostatectomy, respectively. Cystoscopy confirms the diagnosis, while voiding cystourethrography and retrograde urethrogram help assess disease extent. Magnetic resonance imaging may be useful in evaluating complex or previously irradiated patients. Management should be guided by the etiology, severity, and prior interventions, and ranges from endoscopic management to complex reconstruction or diversion. Endoscopic management is the first-line treatment for non-obliterative disease, typically using dilation or direct vision internal urethrotomy. Adjunctive measures such as clean intermittent catheterization or intralesional agents like mitomycin C may improve durability. Novel strategies, including transurethral incision with transverse mucosal realignment and endoscopic grafting, show early promise. Nonetheless, recurrence rates remain high, particularly after radiation. Reconstruction is indicated for obliterative or endoscopically refractory stenoses in patients with preserved bladder function. For BNS, robotic Y-V or T-plasty offers good patency but variable continence, while buccal grafts should be preserved for recurrences. Reanastomosis remains the standard reconstructive surgery for VUAS, though less effective in irradiated patients. Perineal reanastomosis yields high patency but poor continence, while abdominal access may improve continence at a higher technical cost. This review outlines current management strategies for BNS and VUAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.